Atomoxetine, Parent Training, and Their Effects on Sleep in Youth with Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder

Hollway, Jill A.; Mendoza-Burcham, Marrisa; Andridge, Rebecca; Aman, Michael G.; Handen, Benjamin L.; Arnold, L. Eugene; Lecavalier, Luc; Williams, C.; Silverman, Laura B.; Smith, Tristram

doi:10.1089/cap.2017.0085

Cited by 18 publications

(12 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 57 ] Methylphenidate, modafinil and other psychostimulants are effective in the management of these sleep disorders. [ 58 ] Dysregulation of NREM sleep leads to narcolepsy only, whereas; Dys-regulation of REM sleep leads combined narcolepsy with cataplexy. [ 59 ] It has been reported that orexin increases vigilance through increases awaking time and decreases REM and NREM sleep periods.…”

Section: Role Of Orexin In Psychiatric Disordersmentioning

confidence: 99%

Involvement of orexinergic system in psychiatric and neurodegenerative disorders: A scoping review

et al. 2020

View full text Add to dashboard Cite

Orexin is a neuropeptide secreted from lateral hypothalamus and pre-frontal cortex concerned in the wakefulness and excitement. This study aimed to review the possible neurobiological effect of orexin. A diversity of search strategies was adopted and assumed which included electronic database searches of Medline and PubMed using MeSH terms, keywords, and title words during the search. Orexin plays a vital role in activation of learning, memory acquisition, and consolidation through activation of monoaminergic system, which affect cognitive flexibility and cognitive function. Orexin stimulates adrenocorticotropin and corticosteroid secretions via activation of central corticotropin-releasing hormone. Cerebrospinal fluid (CSF) and serum orexin serum levels are reduced in depression, schizophrenia, and narcolepsy. However, high orexin serum levels are revealed in drug addictions. Regarding neurodegenerative brain diseases, CSF and serum orexin serum levels are reduced Parkinson disease, Alzheimer dementia, Huntington's disease, amyotrphic lateral sclerosis, and multiple sclerosis. Orexin antagonist leads to significant reduction of sympathetic over-activity during withdrawal syndrome. As well, orexin antagonist improves sleep pattern. Orexinergic system is involved in the different psychiatric and neurological disorders; therefore, targeting of this system could be possible novel pathway in the management of these disorders. In addition, measurement of CSF and serum orexin levels might predict the relapse and withdrawal of addict patients.

show abstract

Section: Role Of Orexin In Psychiatric Disordersmentioning

confidence: 99%

Involvement of orexinergic system in psychiatric and neurodegenerative disorders: A scoping review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Atomoxetine is less likely to cause insomnia and other sleep issues, and can be considered as a second-choice option. 195,196 Guanfacine and clonidine induce sedation, and may be used alone or in combination with stimulants. [197][198][199] Prescribing a treatment such as melatonin to specifically address sleep issues may be needed in certain individuals.…”

Section: Depressionmentioning

confidence: 99%

Individualization of attention-deficit/hyperactivity disorder treatment: pharmacotherapy considerations by age and co-occurring conditions

et al. 2020

View full text Add to dashboard Cite

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that manifests in childhood and can persist into adolescence and adulthood. Impairments associated with ADHD can impact quality of life, social interactions, and increase the risk of morbidity and mortality; however, for many patients, effective treatment can lessen these effects. Pharmacotherapy with stimulants or nonstimulants is recommended in conjunction with psychosocial therapy for most patients. Determining the optimal pharmacotherapy can be complex, and the clinician needs to consider many factors such as the patient’s age, comorbidities, and lifestyle. Furthermore, the needs of the patient with ADHD will change over time, with specific challenges to consider at each stage of life. A variety of Food and Drug Administration (FDA)-approved stimulant and nonstimulant formulations are available with different modes of delivery and durations of effect. This armamentarium of ADHD medications can be used to individualize ADHD treatment for each patient’s needs. This article combines current information from the literature and the first-hand experience of the authors to provide guidance on ADHD treatment options for patients of different ages and for some of the more common comorbidities.

show abstract

“…Many hypotheses regarding the cause of sleep problems among ASD patients include anxiety, related brain pathologies, and an inability to regulate the sleep hormone melatonin. Sleep disturbances among children with ASD are associated with inadequate melatonin secretion [6-9]. This problem is an important feature that affects social communication, daily life, daytime functioning and behavior, and quality of life and increases parental sleep disruption and stress.…”

Section: Introductionmentioning

confidence: 99%

“…Medication use for sleep disorders is common among children with ASD [12]. Various studies have reported the useful effects of medications such as melatonin for the treatment of sleep disorders among children with ASD [1,6,7]. To date, a structured review study of randomized controlled trials of drug interventions used to treat sleep disorders in patients with ASD.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of drug interventions for the treatment of sleep disorders in children with autism spectrum disorders: a systematic review

Jenabi

Bashirian

2019

Korean J Pediatr

View full text Add to dashboard Cite

A structured review study of drug interventions on sleep disorders in patients with autism spectrum disorders (ASD) has not been published to date. This systematic review aimed to investigate drug interventions for the treatment of sleep disorders in children with ASD. The Web of Science, PubMed, and Scopus databases were searched until March 2019. Study quality was assessed using the Delphi checklist. Due to the heterogeneity of the findings, a meta-analysis was not possible. Drug interventions for the treatment of sleep disorders in patients with ASD included melatonin, atomoxetine, and risperidone. Atomoxetine had no effect on sleep disorders in patients with ASD. A total of 10 studies were reviewed. Melatonin appears to be useful for the treatment of sleep problems in patients with ASD, but further studies are needed to determine the effects of other drugs.

show abstract

Atomoxetine, Parent Training, and Their Effects on Sleep in Youth with Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder

Abstract: ATX appears sleep neutral. Clinicians who treat ADHD symptoms in children and adolescents with ASD may prefer ATX over psychostimulants when sleep disturbance is an issue.

Cited by 18 publications

References 33 publications

Involvement of orexinergic system in psychiatric and neurodegenerative disorders: A scoping review

Involvement of orexinergic system in psychiatric and neurodegenerative disorders: A scoping review

Individualization of attention-deficit/hyperactivity disorder treatment: pharmacotherapy considerations by age and co-occurring conditions

Evaluation of drug interventions for the treatment of sleep disorders in children with autism spectrum disorders: a systematic review

Contact Info

Product

Resources

About